Literature DB >> 17094440

CD2 promoter regulated nucleophosmin-anaplastic lymphoma kinase in transgenic mice causes B lymphoid malignancy.

Suzanne D Turner1, Hartmut Merz, Debra Yeung, Denis R Alexander.   

Abstract

BACKGROUND: Nucleophosmin-anaplastic lymphoma kinase expression is associated with a lymphoid malignancy, anaplastic large cell lymphoma, and is characterized by a t(2;5) chromosomal translocation.
MATERIALS AND METHODS: We describe a novel transgenic mouse line in which NPM-ALK expression is targeted to the T-cell lineage using the CD2 promoter.
RESULTS: Surprisingly, the mice develop B cell lymphomas in the majority of cases.
CONCLUSION: These data stress the importance of choice of promoter to drive transgene expression in obtaining the desired phenotype.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17094440

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  16 in total

Review 1.  Pathobiology of ALK+ anaplastic large-cell lymphoma.

Authors:  Hesham M Amin; Raymond Lai
Journal:  Blood       Date:  2007-05-22       Impact factor: 22.113

2.  The potent oncogene NPM-ALK mediates malignant transformation of normal human CD4(+) T lymphocytes.

Authors:  Qian Zhang; Fang Wei; Hong Yi Wang; Xiaobin Liu; Darshan Roy; Qun-Bin Xiong; Shuguang Jiang; Andrew Medvec; Gwenn Danet-Desnoyers; Christopher Watt; Ewa Tomczak; Michael Kalos; James L Riley; Mariusz A Wasik
Journal:  Am J Pathol       Date:  2013-12       Impact factor: 4.307

3.  CRISPR genome editing of murine hematopoietic stem cells to create Npm1-Alk causes ALK+ lymphoma after transplantation.

Authors:  Soumya Sundara Rajan; Lingxiao Li; Mercedes F Kweh; Kranthi Kunkalla; Amit Dipak Amin; Nitin K Agarwal; Francisco Vega; Jonathan H Schatz
Journal:  Blood Adv       Date:  2019-06-25

4.  Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma.

Authors:  Olaf Merkel; Frank Hamacher; Daniela Laimer; Eveline Sifft; Zlatko Trajanoski; Marcel Scheideler; Gerda Egger; Melanie R Hassler; Christiane Thallinger; Ana Schmatz; Suzanne D Turner; Richard Greil; Lukas Kenner
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-30       Impact factor: 11.205

5.  Anaplastic lymphoma kinase-positive large B-cell lymphoma: a distinct clinicopathological entity.

Authors:  Shiyong Li
Journal:  Int J Clin Exp Pathol       Date:  2009-03-13

6.  A novel model of SCID-X1 reconstitution reveals predisposition to retrovirus-induced lymphoma but no evidence of gammaC gene oncogenicity.

Authors:  Linda Scobie; Ralph D Hector; Louise Grant; Margaret Bell; Anne A Nielsen; Sharon Meikle; Adrian Philbey; Adrain Philbey; Adrian J Thrasher; Adrain J Thrasher; Ewan R Cameron; Karen Blyth; James C Neil
Journal:  Mol Ther       Date:  2009-03-31       Impact factor: 11.454

Review 7.  Molecular Pathogenesis of Peripheral T Cell Lymphoma.

Authors:  Mamiko Sakata-Yanagimoto; Shigeru Chiba
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 4.213

8.  Aberrant anaplastic lymphoma kinase activity induces a p53 and Rb-dependent senescence-like arrest in the absence of detectable p53 stabilization.

Authors:  Fiona Kate Elizabeth McDuff; Suzanne Dawn Turner
Journal:  PLoS One       Date:  2011-03-14       Impact factor: 3.240

9.  Determining the contribution of NPM1 heterozygosity to NPM-ALK-induced lymphomagenesis.

Authors:  Fiona K E Mduff; C Elizabeth Hook; Reuben M Tooze; Brian J Huntly; Pier Paolo Pandolfi; Suzanne D Turner
Journal:  Lab Invest       Date:  2011-06-27       Impact factor: 5.662

10.  Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation.

Authors:  Olaf Merkel; Frank Hamacher; Robert Griessl; Lisa Grabner; Ana-Iris Schiefer; Nicole Prutsch; Constance Baer; Gerda Egger; Michaela Schlederer; Peter William Krenn; Tanja Nicole Hartmann; Ingrid Simonitsch-Klupp; Christoph Plass; Philipp Bernhard Staber; Richard Moriggl; Suzanne D Turner; Richard Greil; Lukas Kenner
Journal:  J Pathol       Date:  2015-04-27       Impact factor: 7.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.